RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E. Walsh(University of Rochester), William C. Gruber(Pfizer (United States)), Nicholas Kitchin(Johns Hopkins University), Kenneth Koury(Johns Hopkins University), Kena A. Swanson(Pfizer (United States)), Kristin Tompkins(University of Rochester), Robert W. Frenck(Naval Medical Research Command), Stephen Lockhart(Johns Hopkins University), Kathrin U. Jansen(Pfizer (United States)), Philip R. Dormitzer(Boston Children's Hospital), Kathleen M. Neuzil(Center for Global Development), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Kirsten E. Lyke(University of Maryland, Baltimore), Mark J. Mulligan(New York University), Alejandra Gurtman(Johns Hopkins University), Warren V. Kalina(Pfizer (United States)), Uğur Şahin(Johannes Gutenberg University Mainz), Vanessa Raabe(Unknown), Judith Absalon(GlaxoSmithKline (United States)), Ann R. Falsey(University of Rochester), Ping Li(Johns Hopkins University), David Cooper(Johns Hopkins University), Özlem Türeci(Johannes Gutenberg University Mainz), Ruth Bailey(Johns Hopkins University), Camila R. Fontes-Garfias(University of Rochester)
Cited by 155
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
|New England Journal of Medicine|2005|2.2k